The case for & against
Bull & Bear analysis
Medtronic plc (NYSE: MDT) is a global leader in medical technology, focusing on innovative therapies across various therapeutic areas including cardiovascular, diabetes management, and surgical solutions. The company’s extensive product portfolio encompasses both established and ground-breaking treatments, including their state-of-the-art cardiac ablation and neurosurgical offerings. With a significant emphasis on innovation for minimally invasive procedures and patient-centered care, Medtronic is strategically positioned in high-growth healthcare markets. Recent product launches and advancements in technologies such as the Affera Mapping and Ablation System reflect its proactive approach to meet evolving patient needs.
Bull says
- ↑Q4 FY26 revenue reached $9.8 B, up 9.9% YoY.
- ↑Cardiac Ablation Solutions grew 78–80% YoY, driving segment momentum.
- ↑Affera Mapping & Ablation System approval strengthens electrophysiology leadership.
- ↑Simplicity hypertension procedure launch could unlock multi‐billion dollar market.
- ↑CapEx rose ~$50 M YoY to fund innovation and strategic M&A.
- ↑Low price volatility and solid balance sheet bolster stability.
Bear says
- ↓Earnings yield and profitability factors are weak, hinting at return challenges.
- ↓Analyst revisions and growth outlook remain negative, dampening expectations.
- ↓Tariffs pose a ~$250 M headwind, risking gross margin compression.
- ↓High short interest reflects investor skepticism on near‐term performance.
- ↓Heavy reliance on new launches like AltaViva and Hugo raises execution risk.
- ↓Intense competition in cardiac and diabetes markets pressures market share.
Investment themes with MDT
Companies paying above-average dividends
Services and products for aging population
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- we started the fiscal year by delivering another consistent quarter of mid-single digit revenue growth.
- we remain confident in our ability to accelerate growth as we move through fiscal 26.
- Our top line growth for the quarter was in line with our guidance, and EPS came in ahead of guidance.
Bear points
- our neuroscience growth was a bit below trend due to our specialty therapies businesses, which was the result of some deliberate changes we'll discuss in a few moments.
- Our adjusted gross margin was 65.1%, down 80 basis points year over year, which was expected due to continued business mix impacting our margins in capital and diabetes.
- we continue to expect fiscal year 26 organic revenue growth of approximately 5%.